Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women
- PMID: 12943520
- DOI: 10.1530/eje.0.1490187
Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women
Abstract
Background: Hyperprolactinemia has been reported to be associated with abnormalities of carbohydrate metabolism. The aim of this study was to evaluate the effects of hyperprolactinemia and bromocriptine (Brc) treatment on endothelial function, insulin sensitivity and inflammatory markers in pre-menopausal women.
Methods: Sixteen hyperprolactinemic pre-menopausal women with pituitary adenomas were recruited and 20 healthy subjects were included as controls. Patients were given Brc in doses of 2.5-20 mg/dl until normal levels of prolactin were reached. Prior to treatment and 2 months after prolactin levels were normalized, the following tests were performed. Insulin sensitivity was determined by an oral glucose tolerance test based on a formula named the insulin sensitivity index (ISI composite). Endothelial function was measured as flow-mediated dilatation (FMD) on a brachial artery using high resolution ultrasound.
Results: Serum glucose, insulin, estrogen, highly sensitive C-reactive protein (hsCRP), fibrinogen, homocysteine and uric acid levels were measured. Calculated ISI composite and FMD were significantly lower in the hyperprolactinemic group in comparison with the controls and improved after Brc treatment. Serum homocysteine, hsCRP and uric acid levels were significantly higher in hyperprolactinemic patients than in the controls and returned to normal levels with Brc treatment. Serum prolactin concentrations were inversely correlated with FMD measurements (r=-0.68; P<0.0001), ISI composite (r=-0.48; P<0.005) and serum estrogen (r=-0.54; P<0.005), and positively correlated with serum homocysteine concentrations (r=0.55; P<0.0001) in the hyperprolactinemic group.
Conclusions: The hyperprolactinemic state is associated with impaired endothelial function and decreased insulin sensitivity, which are early markers of atherosclerosis. These alterations may predispose to the development of atherosclerosis in non-treated cases. Correction of the hyperprolactinemic state is associated with improved endothelial function and insulin sensitivity.
Similar articles
-
The interplay between prolactin and cardiovascular disease.Front Endocrinol (Lausanne). 2023 Jan 10;13:1018090. doi: 10.3389/fendo.2022.1018090. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36704037 Free PMC article. Review.
-
Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study.Pituitary. 2014 Jun;17(3):232-9. doi: 10.1007/s11102-013-0495-z. Pituitary. 2014. PMID: 23756783
-
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.Intern Med. 2001 Sep;40(9):857-61. doi: 10.2169/internalmedicine.40.857. Intern Med. 2001. PMID: 11579944 Clinical Trial.
-
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.Cardiovasc Ther. 2015 Oct;33(5):282-7. doi: 10.1111/1755-5922.12143. Cardiovasc Ther. 2015. PMID: 26146893 Clinical Trial.
-
The effects of hyperprolactinemia on bone and fat.Pituitary. 2009;12(2):96-104. doi: 10.1007/s11102-008-0097-3. Pituitary. 2009. PMID: 18338266 Review.
Cited by
-
Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.Endocrine. 2013 Aug;44(1):193-9. doi: 10.1007/s12020-012-9857-y. Epub 2012 Dec 12. Endocrine. 2013. PMID: 23233277 Clinical Trial.
-
The Influence of Concurrent Autoimmune Thyroiditis on the Cardiometabolic Consequences of Cabergoline in Postmenopausal Women.Metabolites. 2025 Jan 1;15(1):9. doi: 10.3390/metabo15010009. Metabolites. 2025. PMID: 39852352 Free PMC article.
-
What do we know about abnormally low prolactin levels in polycystic ovary syndrome? A narrative review.Rev Endocr Metab Disord. 2024 Dec;25(6):1127-1138. doi: 10.1007/s11154-024-09912-x. Epub 2024 Oct 19. Rev Endocr Metab Disord. 2024. PMID: 39425884 Free PMC article. Review.
-
Prolactin and its 16-kDa N-terminal fragment: are higher in patients with precapillary pulmonary hypertension than in a healthy control group.Tex Heart Inst J. 2012;39(1):44-50. Tex Heart Inst J. 2012. PMID: 22412226 Free PMC article.
-
The interplay between prolactin and cardiovascular disease.Front Endocrinol (Lausanne). 2023 Jan 10;13:1018090. doi: 10.3389/fendo.2022.1018090. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36704037 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials